ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

Anidulafungin Safe And Well-Tolerated In Pediatric Patients With Neutropenia

November 26, 2004

Long-Term Remissions Shown With Chemo Plus Radiation

September 29, 2006

With NIH “Accountability” As Background, Advocates Support Budget Increases.

March 30, 2001

Adcetris Granted Approval For Hodgkin’s Lymphoma and ALCL

September 30, 2011

IOM Report Urges Providers To Address Psychological Needs Of Cancer Patients.

November 23, 2007

Radiosensitizer Screen Concept OK’d, Acoustic Microscopy Delayed

March 2, 1990